Flemington, NJ, United States of America

Peter A Cicala


Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2012

Loading Chart...
1 patent (USPTO):

Title: Innovations by Peter A. Cicala: A Pioneer in Platelet Lowering Agents

Introduction

Peter A. Cicala, located in Flemington, NJ, has made significant contributions to the field of medicinal chemistry through his innovative work in platelet lowering agents. With a focus on improving patient safety and compliance in the treatment of myeloproliferative diseases, Cicala is recognized for his groundbreaking invention in the pharmaceutical landscape.

Latest Patents

Peter A. Cicala holds a patent for "Substituted quinazolines for reducing platelet count." This invention pertains to the discovery of prodrugs of 3- or 5-substituted analogues of the selective platelet lowering agent anagrelide. The prodrugs developed by Cicala exhibit a reduced potential for cardiovascular side-effects, thereby enhancing patient safety and compliance. Specifically, these compounds function by inhibiting platelet formation in humans. One notable compound from his patent includes methyl 2-(2-amino-5,6-dichloroquinazolin-3 (4H)-yl)-2-methylpropanoate.

Career Highlights

Peter A. Cicala has dedicated his career to advancing the development of innovative pharmaceutical solutions. His work at Shire LLC has provided him with a platform to explore new medicinal compounds that can reduce platelet counts while minimizing adverse side effects. Cicala's research is pivotal in enhancing the treatment protocols for patients suffering from blood disorders.

Collaborations

Throughout his career, Cicala has collaborated with esteemed professionals in the field, including Richard Franklin and Bernard Thomas Golding. These partnerships have fostered a collaborative environment conducive to innovation and the development of effective medical treatments that address crucial healthcare needs.

Conclusion

In summary, Peter A. Cicala's inventive contributions, particularly in the realm of platelet lowering agents, reflect his dedication to improving patient outcomes. His patent for substituted quinazolines represents a significant advancement in pharmacology, showcasing the importance of innovation in creating safer and more efficient treatments for myeloproliferative diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…